Research in MicroRNA Profiling of Prostate Cancer (Volume II)

Dear Colleagues,

Prostate cancer (PCa) is the most common non-cutaneous cancer with a high mortality rate among men in the Western world.

Despite the advancements in the management of PCa, there are still many clinical challenges that need to be tackled. Both the detection and treatment monitoring of PCa still rely on prostate-specific antigen (PSA) as the main biomarker for the disease. Nevertheless, both the diagnostic and prognostic values of PSA are quite limited due to its low sensitivity and specificity.

MicroRNAs (miRNAs) seem to be quite promising alternative biomarkers in this context. There is evidence to suggest that miRNAs may play a crucial role in malignant transformation, tumor growth, and spread. Studies have shown that miRNAs are expressed abnormally in various cancers, including PCa, suggesting that they play a pivotal role in cancer development and progression. The importance of miRNAs in the development of PCa has been illustrated by a series of interactions between miRNAs and mRNA influencing carcinogenesis. It is assumed that dysregulated miRNAs are important for altered cell growth and invasion; thus, they may be crucial for the metastatic potential of PCa. However, the exact role of PCa-specific miRNAs in the prevention, diagnosis, and treatment of PCa needs to be clarified.

In this second edition of our Special Issue (Research in MicroRNA Profiling of Prostate Cancer), we would like to continue to explore  the role of miRNAs as potential alternative diagnostic, predictive, and prognostic biomarkers for PCa.

Prof. Dr. Palle Jörn Sloth Osther
Dr. Ahmed H. Zedan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• microRNAs
• prostate cancer
• radiotherapy
• prostatectomy
• chemotherapy
• mCRPC
• new hormonal agents
• prognostic biomarker
• qPCR
• ISH